• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Altimmune Announces Second Quarter 2025 Financial Results and Business Update

    8/12/25 7:00:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALT alert in real time by email

    Positive data from the IMPACT Phase 2b trial reinforces the potential for pemvidutide to be a highly differentiated MASH therapy

    Pemvidutide is the first product candidate to achieve statistically significant MASH resolution and weight loss at 24 weeks

    New data from the IMPACT trial demonstrates potentially class-leading improvements in corrected T1 (cT1), an important marker of liver inflammation and fibrosis

    End-of-Phase 2 Meeting with FDA expected in Q4 2025

    Cash, cash equivalents and short-term investments of $183.1 million as of June 30, 2025

    Webcast to be held today, August 12, 2025, at 8:30 a.m. ET

    GAITHERSBURG, Md., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for liver and cardiometabolic diseases, today announced financial results for the second quarter ended June 30, 2025 and provided a business update.

    "Pemvidutide demonstrated rapid and robust MASH effects, meaningful weight loss and impressive safety and tolerability in the recently reported results from the IMPACT Phase 2b trial," said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. "We are preparing for an End-of-Phase 2 Meeting with the FDA which will position us well for Phase 3 development. In addition, we look forward to reporting the full 48-week data in the fourth quarter and providing further updates as we continue to advance pemvidutide."

    Dr. Scott Harris, Chief Medical Officer of Altimmune, commented, "The improvements in cT1 observed in the IMPACT trial were potentially class-leading among MASH clinical trials to-date. Reductions in cT1 are correlated with MASH resolution and fibrosis improvement. These new data along with the previously reported results from non-invasive tests of fibrosis, further strengthen the potential therapeutic value of pemvidutide."

    Recent Highlights and Anticipated Milestones

    Metabolic Dysfunction-Associated Steatohepatitis (MASH)

    • Reported positive 24-week top-line data from the IMPACT Phase 2b trial
      • Statistically significant MASH resolution without worsening of fibrosis was observed in up to 59.1% of patients receiving pemvidutide
      • Fibrosis improvement without worsening of MASH was observed in up to 34.5% of pemvidutide-treated patients
      • Statistically significant improvements were observed across multiple objective measures of fibrosis, including supplemental AI-based analyses and non-invasive tests (NITs) of liver fibrosis, Enhanced Liver Fibrosis (ELF) score and Vibration-Controlled Transient Elastography (VCTE)
      • Statistically significant weight loss of up to 6.2% at 24 weeks with a trajectory of continuing weight loss
      • Potential for best-in-class tolerability without dose titration
        • Fewer adverse event-related discontinuations with pemvidutide vs placebo
        • Less than 1% treatment discontinuations due to adverse events in pemvidutide-treated patients
    • New data on corrected T1 (cT1) imaging demonstrates potentially class-leading improvements in pemvidutide-treated patients
      • cT1 is a highly reproducible MRI-based imaging method that measures the magnitude of liver inflammation and fibrosis. Decreases in cT1 relaxation time of 80 milliseconds (ms) or greater have been correlated with improvements in liver inflammation and fibrosis in clinical studies.
      • In an analysis of imaging data from the IMPACT trial, mean decreases from baseline in cT1 relaxation time were 145.0 ms and 147.9 ms in the pemvidutide 1.2 mg and 1.8 mg groups, respectively, compared with a decrease of 27.5 ms in placebo (p < 0.001 for both)
    • The IMPACT trial is ongoing with data on weight loss, NITs and safety at 48 weeks of treatment expected in the fourth quarter of 2025
    • End-of-Phase 2 Meeting with FDA targeted for fourth quarter of 2025

    Alcohol Use Disorder (AUD)

    • Announced in May 2025 the initiation of RECLAIM, a Phase 2 trial evaluating the safety and efficacy of pemvidutide in AUD
      • RECLAIM is a randomized, placebo-controlled trial expected to enroll approximately 100 subjects, randomized 1:1, to receive either 2.4 mg pemvidutide or placebo weekly for 24 weeks
      • The primary endpoint of the trial is the change from baseline in the average number of heavy drinking days per week at 24 weeks
      • Key secondary endpoints include the proportion of subjects achieving a 2-level reduction in World Health Organization (WHO) risk drinking level and absolute change from baseline in average levels of phosphatidylethanol (PEth) a serum biomarker of alcohol intake

    Alcohol-Associated Liver Disease (ALD)

    • Announced in July 2025 the initiation of RESTORE, a Phase 2 trial evaluating the safety and efficacy of pemvidutide in ALD
      • RESTORE is a randomized, placebo-controlled trial expected to enroll approximately 100 subjects, randomized 1:1 to receive either 2.4 mg pemvidutide or placebo weekly for 48 weeks
      • The primary endpoint of the trial is the change from baseline in liver stiffness measurement (LSM), as measured by VCTE, at week 24
      • Key secondary endpoints include the change from baseline in LSM at week 48, changes in ELF score at weeks 24 and 48, and changes in alcohol consumption and body weight at both 24 and 48 weeks

    Corporate Update

    • Jerry Durso appointed by Altimmune Board of Directors to succeed Mitchel Sayare, Ph.D. as Chairman
      • Appointment is part of the Board's ongoing succession planning. It recognizes Mr. Durso's extensive commercial and corporate development expertise and aligns with Altimmune's planned advancement into Phase 3 development of pemvidutide in MASH.
      • Dr. Sayare to continue to serve on the Board as an Independent Director

    Financial Results for the Three Months Ended June 30, 2025

    • Altimmune reported cash, cash equivalents and short-term investments totaling $183.1 million as of June 30, 2025, a 39% increase as compared to $131.9 million at December 31, 2024
    • Research and development expenses were $17.2 million for the three months ended June 30, 2025, compared to $21.2 million in the same period in 2024, the decrease resulting from timing of clinical trial costs. The expenses for the quarter ended June 30, 2025, included $11.2 million in direct costs related to pemvidutide development activities
    • General and administrative expenses were consistent period-over-period at $5.7 million and $5.6 million for the three months ended June 30, 2025 and 2024, respectively
    • Interest income was $1.1 million for the three months ended June 30, 2025
    • Net loss for the three months ended June 30, 2025, was $22.1 million, or $0.27 net loss per share, compared to a net loss of $24.6 million, or $0.35 net loss per share, in the same period in 2024

    Conference Call Information:

    Date:August 12, 2025
    Time:8:30 a.m. Eastern Time
    Webcast:To listen, the conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors.
    Dial-in:To participate or dial-in, register here to receive the dial-in numbers and unique PIN to access the call.
      

    Following the conclusion of the call, the webcast will be available for replay on the Investor Relations (IR) page of the Company's website at www.altimmune.com. The Company has used, and intends to continue to use, the IR portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.

    About Pemvidutide

    Pemvidutide is a novel, investigational, peptide-based 1:1 GLP-1/glucagon dual receptor agonist in development for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH), Alcohol Use Disorder (AUD), Alcohol-Associated Liver Disease (ALD) and obesity. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, which is believed to lead to rapid reductions in levels of liver fat and serum lipids. In the ongoing IMPACT Phase 2b trial, at Week 24, once-weekly pemvidutide demonstrated statistically significant MASH resolution without worsening of fibrosis, positive trends in liver fibrosis stage improvement without worsening of MASH, statistically significant reductions in non-invasive tests of fibrosis, weight loss, and liver fat content, and improvements in blood pressure. In a post-hoc AI-based analysis of the biopsies from the IMPACT trial, pemvidutide achieved a statistically significant reduction in liver fibrosis. In earlier trials, pemvidutide also demonstrated class-leading lean mass preservation and robust reductions in triglycerides and LDL cholesterol. Pemvidutide was well tolerated in the IMPACT trial, demonstrating potentially best-in-class tolerability among drugs in development for MASH with very low rates of discontinuation due to adverse events. The U.S. FDA granted Fast Track designation to pemvidutide for the treatment of MASH. The ongoing IMPACT Phase 2b MASH trial 48-week readout is expected in Q4 2025. In addition, RECLAIM, a Phase 2 trial in AUD and RESTORE, a Phase 2 trial in ALD, were initiated in May 2025 and July 2025, respectively.

    About Altimmune

    Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company's lead program is pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of MASH, Alcohol Use Disorder (AUD), Alcohol-Associated Liver Disease (ALD) and obesity. For more information, please visit www.altimmune.com.

    Follow @Altimmune, Inc. on LinkedIn

    Follow @AltimmuneInc on X

    Forward-Looking Statement

    Any statements made in this press release related to the development or commercialization of pemvidutide, an investigational product candidate, and other business and financial matters including without limitation, clinical trial study design, status, correspondence, results and data, including the ongoing RECLAIM, RESTORE and IMPACT Trials, the timing of key milestones for the Company's clinical assets, future plans or expectations for pemvidutide for the treatment of MASH, AUD, ALD and obesity, and the prospects for receiving regulatory approval or commercializing or selling any product or drug candidates, and the impact of the changes to our leadership and governance structure, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to Altimmune, Inc. may identify forward-looking statements. The Company cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including risks relating to: delays in regulatory review, manufacturing and supply chain interruptions, access to clinical sites, enrollment, adverse effects on healthcare systems and disruption of the global economy; the reliability of the results of studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates; the Company's ability to manufacture clinical trial materials on the timelines anticipated; and the success of future product advancements, including the success of future clinical trials. Further information on the factors and risks that could affect the Company's business, financial conditions and results of operations are contained in the Company's filings with the U.S. Securities and Exchange Commission, including under the heading "Risk Factors" in the Company's most recent annual report on Form 10-K, quarterly report on Form 10-Q and the Company's other filings with the SEC, which are available at www.sec.gov.

    Company Contact:

    Greg Weaver

    Chief Financial Officer

    Phone: 240-654-1450

    [email protected]

    Investor Contact:

    Lee Roth

    Burns McClellan

    Phone: 646-382-3403

    [email protected]

    Media Contact:

    Jake Robison

    Inizio Evoke Comms

    Phone: 619-849-5383

    [email protected]



    ALTIMMUNE, INC.

    CONSOLIDATED BALANCE SHEETS

    (In thousands, except share and per-share amounts)
     
         June 30,  December 31, 
      2025 2024
      (Unaudited)   
    ASSETS      
    Current assets:      
    Cash and cash equivalents $183,105  $36,926 
    Restricted cash  42   42 
    Total cash, cash equivalents and restricted cash  183,147   36,968 
    Short-term investments  —   94,965 
    Accounts and other receivables  321   544 
    Income tax and R&D incentive receivables  557   2,573 
    Prepaid expenses and other current assets  4,397   2,204 
    Total current assets  188,422   137,254 
    Property and equipment, net  364   413 
    Other assets  1,564   1,639 
    Total assets $190,350  $139,306 
    LIABILITIES AND STOCKHOLDERS' EQUITY      
    Current liabilities:      
    Accounts payable $851  $211 
    Accrued expenses and other current liabilities  8,369   10,257 
    Total current liabilities  9,220   10,468 
    Term loan, noncurrent  14,332   — 
    Other noncurrent liabilities  5,431   5,330 
    Total liabilities  28,983   15,798 
    Commitments and contingencies      
    Stockholders' equity:      
    Stockholders' equity:  9   7 
    Additional paid-in capital  769,508   689,864 
    Accumulated deficit  (603,111)  (561,390)
    Accumulated other comprehensive loss, net  (5,039)  (4,973)
    Total stockholders' equity  161,367   123,508 
    Total liabilities and stockholders' equity $190,350  $139,306 



    ALTIMMUNE, INC.

    CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

    (Unaudited)

    (In thousands, except share and per-share amounts)
                 
      Three Months Ended  Six Months Ended
      June 30,  June 30, 
      2025    2024    2025    2024
    Revenues $5  $5  $10  $10 
    Operating expenses:            
    Research and development  17,236   21,155   33,063   42,642 
    General and administrative  5,691   5,595   11,684   10,907 
    Total operating expenses  22,927   26,750   44,747   53,549 
    Loss from operations  (22,922)  (26,745)  (44,737)  (53,539)
    Other income (expense):            
    Interest expense  (264)  (1)  (265)  (2)
    Interest income  1,132   2,182   2,677   4,595 
    Other income (expense), net  (92)  (76)  (77)  (88)
    Total other income (expense), net  776   2,105   2,335   4,505 
    Net loss before income taxes  (22,146)  (24,640)  (42,402)  (49,034)
    Income tax expense (benefit)  —   —   (681)  — 
    Net loss  (22,146)  (24,640)  (41,721)  (49,034)
    Other comprehensive income — unrealized loss on short-term investments  (36)  (31)  (66)  (188)
    Comprehensive loss $(22,182) $(24,671) $(41,787) $(49,222)
    Net loss per share, basic and diluted $(0.27) $(0.35) $(0.53) $(0.69)
    Weighted-average common shares outstanding, basic and diluted  81,477,548   70,924,371   78,529,028   70,863,042 

    This press release was published by a CLEAR® Verified individual.



    Primary Logo

    Get the next $ALT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALT

    DatePrice TargetRatingAnalyst
    7/10/2025$1.00Sell
    Goldman
    2/28/2025Mkt Perform
    William Blair
    1/8/2025$18.00Buy
    Stifel
    11/12/2024$26.00Buy
    UBS
    4/29/2024Buy → Neutral
    Guggenheim
    1/24/2024$13.00Neutral
    Goldman
    3/22/2023$20.00 → $6.00Buy → Neutral
    Goldman
    12/1/2022$20.00Buy
    Goldman
    More analyst ratings

    $ALT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman resumed coverage on Altimmune with a new price target

    Goldman resumed coverage of Altimmune with a rating of Sell and set a new price target of $1.00

    7/10/25 8:47:17 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    William Blair initiated coverage on Altimmune

    William Blair initiated coverage of Altimmune with a rating of Mkt Perform

    2/28/25 7:17:56 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel initiated coverage on Altimmune with a new price target

    Stifel initiated coverage of Altimmune with a rating of Buy and set a new price target of $18.00

    1/8/25 7:32:53 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide

    Seasoned clinical leader to oversee Phase 3 development of pemvidutide in MASH Dr. Arbet-Engels has led late-stage development, regulatory approvals and commercial launches for multiple successful franchises GAITHERSBURG, Md., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the appointment of Christophe Arbet-Engels, MD, PhD as Chief Medical Officer, effective October 1, 2025. Dr. Arbet-Engels joins the Company with more than 30 years of experience spanning industry, academia and private practice, and will lead the ongoing c

    9/29/25 7:30:11 AM ET
    $ALT
    $XFOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Altimmune to Participate in Two Upcoming Investor Conferences

    GAITHERSBURG, Md., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company's management team will participate and be available for 1x1 meetings at the following investor conferences: Stifel 2025 Virtual Cardiometabolic ForumTuesday, September 30, 2025Fireside Chat at 10:30 a.m. Eastern Time H.C. Wainwright Liver Disease Virtual ConferenceTuesday, October 21, 2025Fireside Chat at 7:00 a.m. Eastern Time The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.

    9/23/25 7:30:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer

    GAITHERSBURG, Md., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the appointment of Linda M. Richardson to the role of Chief Commercial Officer, effective September 16, 2025. Ms. Richardson joins the Company with more than 30 years of experience in sales and marketing, commercial, corporate and business development across a range of therapeutic areas, including metabolic disease, hepatology, cardiovascular and addiction medicine. During her career, she has led multiple product launches, built successful commercial franchises

    9/15/25 7:30:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    SEC Filings

    View All

    Altimmune Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Altimmune, Inc. (0001326190) (Filer)

    9/25/25 4:07:15 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Altimmune Inc.

    DEF 14A - Altimmune, Inc. (0001326190) (Filer)

    8/15/25 4:11:17 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Altimmune Inc.

    10-Q - Altimmune, Inc. (0001326190) (Filer)

    8/12/25 10:15:21 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Sohn Catherine A. bought $5,784 worth of shares (1,000 units at $5.78) (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    3/18/25 4:15:22 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Weaver Gregory L bought $51,996 worth of shares (10,000 units at $5.20) (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    3/14/25 7:27:34 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Sohn Catherine A.

    4 - Altimmune, Inc. (0001326190) (Issuer)

    9/29/25 4:21:00 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Durso Jerome Benedict

    4 - Altimmune, Inc. (0001326190) (Issuer)

    9/29/25 4:20:03 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Lawver Teri L

    4 - Altimmune, Inc. (0001326190) (Issuer)

    9/29/25 4:19:09 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    Leadership Updates

    Live Leadership Updates

    View All

    Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide

    Seasoned clinical leader to oversee Phase 3 development of pemvidutide in MASH Dr. Arbet-Engels has led late-stage development, regulatory approvals and commercial launches for multiple successful franchises GAITHERSBURG, Md., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the appointment of Christophe Arbet-Engels, MD, PhD as Chief Medical Officer, effective October 1, 2025. Dr. Arbet-Engels joins the Company with more than 30 years of experience spanning industry, academia and private practice, and will lead the ongoing c

    9/29/25 7:30:11 AM ET
    $ALT
    $XFOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer

    GAITHERSBURG, Md., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the appointment of Linda M. Richardson to the role of Chief Commercial Officer, effective September 16, 2025. Ms. Richardson joins the Company with more than 30 years of experience in sales and marketing, commercial, corporate and business development across a range of therapeutic areas, including metabolic disease, hepatology, cardiovascular and addiction medicine. During her career, she has led multiple product launches, built successful commercial franchises

    9/15/25 7:30:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Altimmune Board of Directors Appoints Jerry Durso as Chairman

    Appointment recognizes Mr. Durso's extensive commercial expertise as Altimmune prepares for Phase 3 development of pemvidutide in MASH Mitchel Sayare, Ph.D., to remain on the Board as Independent Director GAITHERSBURG, Md., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that its Board of Directors has appointed Jerry Durso as Chairman, effective August 12, 2025. Mr. Durso succeeds Mitchel Sayare, Ph.D., who will continue to serve on the Board as an Independent Director. The leadership transition is part of the Board's

    8/11/25 7:30:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    Financials

    Live finance-specific insights

    View All

    Altimmune Announces Second Quarter 2025 Financial Results and Business Update

    Positive data from the IMPACT Phase 2b trial reinforces the potential for pemvidutide to be a highly differentiated MASH therapy Pemvidutide is the first product candidate to achieve statistically significant MASH resolution and weight loss at 24 weeks New data from the IMPACT trial demonstrates potentially class-leading improvements in corrected T1 (cT1), an important marker of liver inflammation and fibrosis End-of-Phase 2 Meeting with FDA expected in Q4 2025 Cash, cash equivalents and short-term investments of $183.1 million as of June 30, 2025 Webcast to be held today, August 12, 2025, at 8:30 a.m. ET GAITHERSBURG, Md., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:A

    8/12/25 7:00:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025

    GAITHERSBURG, Md., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2025 financial results on Tuesday, August 12, 2025. Altimmune management will host a conference call at 8:30 am E.T. on August 12 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor R

    8/5/25 7:30:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH

    First product candidate to demonstrate significant MASH effects and weight loss at 24 weeks Trial met its primary endpoint with statistically significant MASH resolution without worsening of fibrosis in up to 59.1% of participants in an ITT analysis Fibrosis improvement without worsening of MASH in up to 34.5% of participants in an ITT analysis Supplemental AI-based analysis demonstrated statistically significant reductions in liver fibrosis at 24 weeks Weight loss of up to 6.2% at 24 weeks with no plateauing Potentially best-in-class tolerability, with less than 1% treatment discontinuations due to adverse events in pemvidutide-treated participants Conference call to be held on June 2

    6/26/25 7:00:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Altimmune Inc.

    SC 13G/A - Altimmune, Inc. (0001326190) (Subject)

    11/14/24 11:58:56 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Altimmune Inc.

    SC 13G/A - Altimmune, Inc. (0001326190) (Subject)

    10/17/24 11:16:51 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Altimmune Inc.

    SC 13G/A - Altimmune, Inc. (0001326190) (Subject)

    10/16/24 4:21:16 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care